Blixeprodil

Evidence outlook · lead readout

NCT06309277 · Major Depressive Disorder

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT06309277: The study was randomized, quadruple-blind, placebo-controlled, and included 46 participants, but the primary endpoint was treatment-emergent adverse-event incidence rather than an efficacy endpoint. The registry reports adverse-event counts but no statistical comparison for this primary endpoint, so whether it was met is unclear; the depression-rating result was a statistically significant secondary finding.